Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-12 04:31:30 EDT

Explore

PostsPeople
LatestRanked
Load more
@midgardfinance.comOct 1, 2026, 3:30 PM

💉 #pharma #EASD2026

🇺🇸 $LLY #eloralintide added 8.5 points of weight loss to tirzepatide in type 2 diabetes: 23.3% vs 14.8%, 48 wk.

🇩🇰 $NOVO #CagriSema: 4.0 added to semaglutide, 14.2% vs 10.2%, 68 wk. One-molecule #zenagamtide: 14.6%, 36 wk.

Separate trials.

midgardfinance.com/diabetes/

Chart titled "Amylin added 8.5 points to tirzepatide, 4.0 to semaglutide". Three rows, each a separate trial in adults with type 2 diabetes, showing the average weight loss at the top dose as estimated for people staying on treatment. Top row, Lilly, two molecules, phase 2b, 48 weeks: a grey point for tirzepatide 15 mg alone at 14.8 per cent joined to a red point for the same dose with eloralintide 9 mg at 23.3 per cent. Middle row, Novo, two molecules, the REIMAGINE 2 trial, phase 3, 68 weeks: a grey point for semaglutide 2.4 mg alone at 10.2 per cent joined to a blue point for the same dose with cagrilintide 2.4 mg at 14.2 per cent. Bottom row, Novo, one molecule, phase 2, 36 weeks: a single blue point for zenagamtide 40 mg at 14.6 per cent, marked as having no arm without amylin, because both actions are in the same molecule. The rows are not a ranking: the trials differ in length, stage and participants, and only the gap inside a row compares like with like.
@springermedicine.comOct 1, 2026, 3:15 PM

With #EASD2026 soon coming to a close, we bring you the key updates and latest advances in #diabetes research, treatment, and care from this year's meeting.

👉️ buff.ly/7GIjfiy

#MedSky

@thelancet.comOct 1, 2026, 3:07 PM

Presented at #EASD2026—Mauritius is the first country to show a decreasing prevalence of diabetes and intermediate hyperglycaemia over time, using the objective, gold standard OGTT-based diagnostic criteria recommended by WHO. More in @thelancetendo.bsky.social: spkl.io/633217pvTl

Section of the first page of an article published in The Lancet Diabetes & Endocrinology entitled "Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study".
@arc-em.bsky.socialOct 1, 2026, 3:06 PM

A new review published in @thelancetendo.bsky.social argues primary care is fundamental to tackling the rising number of people living with diabetes worldwide.

Our researchers are among the authors, and it was presented today at #EASD2026 in Milan.

Read more:
🔗 arc-em.nihr.ac.uk/news/primary...

@easdnews.bsky.socialOct 1, 2026, 2:40 PM

🔴 Happening now live from #EASD2026: #Diabetes technologies during hospitalisation!

Prof. David O'Neal on future perspectives, following Prof. Mikkel Thor Olsen. Chaired by Kirsten Nørgaard.

🔬 Thanks to all who joined us in the Arena and to our speakers & chair for such an insightful session!

@midgardfinance.comOct 1, 2026, 2:00 PM

💊 #pharma #EASD2026

🇺🇸 $LLY #orforglipron, a daily pill, vs insulin glargine in type 2 diabetes at high CV risk (ACHIEVE-4, n=2,749): major CV events HR 0.84 (0.59-1.20). Non-inferior, not shown better.

Deaths HR 0.43 (0.25-0.75), not a formally tested endpoint.

midgardfinance.com/diabetes/

Forest plot titled "Orforglipron pill vs insulin glargine", from Lilly's ACHIEVE-4 trial in 2,749 adults with type 2 diabetes, obesity or overweight and raised cardiovascular risk. Four hazard ratios with 95% intervals on a log axis from 0.2 to 2, with a vertical line at 1; below 1 favours the pill. MACE-4 (primary): 0.84 (0.59-1.20). MACE-3: 0.77 (0.52-1.13). Cardiovascular death: 0.47 (0.25-0.90). Death, any cause: 0.43 (0.25-0.75). The first two, drawn in grey, were the tested endpoints and their intervals cross 1: the pill met non-inferiority (limit 1.8) and was not shown to be better. The two death endpoints, in purple, sit below 1 but were not controlled for multiple testing. Open-label trial, median follow-up two years; the primary endpoint occurred in 57 of 1,358 on the pill and 67 of 1,343 on insulin. At week 52, counting all randomised patients, HbA1c fell 1.5 points on the pill and 1.0 on insulin; weight changed -7.8% and +1.1%.
@salutedomani.bsky.socialOct 1, 2026, 1:20 PM

Obesita’ e steatosi epatica: semaglutide riduce il grasso nel fegato in 9 adulti su 10 #EASD2026

Presentati oggi a Milano, in occasione del 62° Congresso annuale della European Association for the Study of Diabetes (EASD), i dati di un’analisi post hoc dello studio STEP UP di Novo. L’analisi,…

@explora-guide78.bsky.socialOct 1, 2026, 1:03 PM

You came to Milan with work

Explore the city at your own pace - even if you only have 20 minutes.

Open Explora → Special Collections
Enter code: DIABETES-MILAN

explora.guide/conference/

#Milan #Diabetes #EASD2026

@midgardfinance.comOct 1, 2026, 12:30 PM

💉 #obesity #EASD2026

🇩🇪 Boehringer's #survodutide, from 🇩🇰 Zealand, in obesity with type 2 diabetes. Phase 3, NEJM:

Weight, all randomised: -9.8% vs -3.9% placebo
On treatment: -13.1%
Stopped for side effects: 26% vs 9%. Four rivals: 6-11%

midgardfinance.com/obesity/drugs/survodutide/

$ZEAL

Scatter chart of five obesity drugs in their phase 3 trials in adults with obesity and type 2 diabetes, one point per drug at its top dose. Across: the share of patients who stopped the drug because of side effects. Down: average weight change counting all randomised patients. Semaglutide 7.2 mg (STEP UP T2D, 72 weeks): 6 per cent stopped, weight -13.2 per cent. Retatrutide 12 mg (TRIUMPH-2, 80 weeks): 7 per cent stopped, weight -18.8 per cent. CagriSema 2.4/2.4 mg (REDEFINE 2, 68 weeks): 8 per cent stopped, weight -13.7 per cent. Orforglipron 36 mg (ATTAIN-2, 72 weeks): 11 per cent stopped, weight -9.6 per cent. Survodutide 6 mg (SYNCHRONIZE-2, 76 weeks): 26 per cent stopped, weight -9.8 per cent. Four of the points sit between 6 and 11 per cent stopping; survodutide is alone on the right at 26 per cent, with about the same weight loss as the oral drug orforglipron. Survodutide's trial was published in the New England Journal of Medicine on 1 October 2026. These are separate trials with different participants and lengths, not a head-to-head comparison. Tirzepatide is not shown because its trial's published summary gives no comparable figure for stopping.
@diabetologiajnl.bsky.socialOct 1, 2026, 11:55 AM

In our 2026 special issue: Pharmacological treatment of #MASH link.springer.com/article/10.1... #EASD2026

@springermedicine.comOct 1, 2026, 10:54 AM

From #EASD2026 - The first consensus recommendations for the use of #GLP1 receptor agonists during preconception, pregnancy, and the postnatal period in women with diabetes have been published.

Read the full story 👉️ buff.ly/KEfCaam

#MedNews

@redgdps.bsky.socialOct 1, 2026, 10:49 AM

El comentario del Dr. Manuel Ruiz Quintero (@maruizquintero ) en este post de #EASD2026
⭕️ Terapia combinada temprana frente a terapia escalonada: replanteamiento del tratamiento de la #diabetes
"Tratar sin prisa, pero sin pausa"
Leer en:
redgedaps.blogspot.com/2026/10/easd...

@easdnews.bsky.socialOct 1, 2026, 10:46 AM

📖 POV: You’re an EASD Pocket Programme at #EASD2026.

Passed from hand to hand. Squashed in bags. Scribbled on. Lost and found. 😅 Yet somehow, it still has all the answers.

📷 Check out a day in the life…

#EASDEntertainment #ScientificProgramme #PocketProgramme #Diabetes

@thelancetendo.bsky.socialOct 1, 2026, 10:41 AM

New—Diabetes and the role of primary care: a global perspective thelancet.com/journals/lan...
#diabetes
#EASD2026

#MedSky #EndoSky

@metabologiajnl.bsky.socialOct 1, 2026, 10:35 AM

Metabologia wants your research papers on the #metabolic aspects of #diabetes, #obesity #CVD and #renal and #hepatic disease #comorbidity #nutrition #exercise #psychosocial #healtheconomics #healthtechnology – submit now! metabologia.org #EASD2026

@conscienhealth.bsky.socialOct 1, 2026, 10:10 AM

Does @elilillyandcompany.bsky.social have a winner in #EloraTZP for obesity in diabetes? Data from #EASD2026 suggests it might.
conscienhealth.org/2026/10/01/e...

@practicaldiabetic.bsky.socialOct 1, 2026, 10:08 AM

Comparing intermittent energy restriction to time restriction eating, IER led to more weight loss. Neither improved HbA1c but both reduced the need for T2D medication in 2/3 of participants. #EASD2026 #dedoc⁰

@thelancetendo.bsky.socialOct 1, 2026, 9:33 AM

#AI has substantial potential in screening, classifying, predicting, and preventing #diabetes. In primary care, AI-driven solutions can provide personalised treatment plans and empower self-management www.thelancet.com/journals/lan...
#T1D #T2D
#EASD2026

#MedSky #EndoSky

@practicaldiabetic.bsky.socialOct 1, 2026, 9:15 AM

Second low carb study over 6 months showed no significant change in LDL with best adherence with a moderately low carb and improvements in TIR and TAR. 2/3 of participants dropped out of the low carb diet and there were 3 severe hypos. #EASD2026 #dedoc⁰

@practicaldiabetic.bsky.socialOct 1, 2026, 9:02 AM

The weight loss was comparable to the conventional diabetes diet however the presenter confirmed LDL was increased in the high protein diet. #EASD2026 #dedoc⁰